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Abstract 
Two serology-based staging models of patients with hepatocellular carcinoma (HCC), 
the BALAD and BALAD-2 models, were applied to a Japanese cohort of a nationwide 
follow-up survey of HCC. The ability of these models to predict the progression of 
HCC and the deterioration of liver function and to assess prognosis was evaluated. 
BALAD and BALAD-2 scores were calculated in 6816 patients from a cohort of 
Japanese nationwide survey based on the serum levels of five markers (bilirubin, 
albumin, lens culinaris agglutinin-reactive alpha-fetoprotein, alpha-fetoprotein, and 
des-gamma-carboxy prothrombin) measured at the time of HCC diagnosis. The 
associations of these scores with the progression of HCC and liver function and with 
survival rates were analyzed. There were good correlations between BALAD and 
BALAD-2 scores and the progression of HCC and Child-Pugh class. Both staging 
scores accurately categorized patients into risk groups with different survival rates. 
BALAD-2 showed superior discrimination of patient survival compared with the 
original BALAD. Conclusions: Serology-based staging models, especially the 
BALAD-2 model, were useful for staging and prognostication of survival in a cohort of 
Japanese patients with HCC from a nationwide survey. 
 
  
Introduction 
     We previously proposed a serology-based staging system for hepatocellular 
carcinoma (HCC), the BALAD scoring model, for assessing the prognosis of patients 
with HCC (1). This scoring system is based solely on the serum levels of five 
parameters, namely, total bilirubin (T-Bil), albumin (ALB), lens culinaris agglutinin 
A-reactive fraction of alpha-fetoprotein (AFP-L3), alpha-fetoprotein (AFP), and 
des-gamma-carboxy prothrombin (DCP). The model predicted the outcome of patients 
with HCC with high discrimination (1). Recently, Fox et al. proposed an improved 
serologic staging model, BALAD-2, that was developed using a more sophisticated 
statistical method that treated variables in a continuous manner (2). Both BALAD and 
BALAD-2 were shown to have excellent prognostic discrimination in international 
settings (2, 3), despite large differences across regions in both HCC progression and 
survival after diagnosis. 
     In the present study, we applied these two serologic staging models to 24029 
patients with HCC in Japan, where surveillance of HCC is established and patients are 
diagnosed with HCC earlier and have longer survival than in Western and other Asian 
countries. Since 1965, the Liver Cancer Study Group of Japan (LCSGJ) has been 
conducting biannual nationwide follow-up surveys and prospectively collecting data on 
patients with HCC in Japan. We conducted this retrospective study based on these 
prospectively collected data which included variables for BALAD and BALAD-2 
scores. 
 
Patients and Methods 
Patients and Treatments 
     A total of 66554 patients with primary liver cancer were prospectively registered 
biannually by LCSGJ from more than 750 participating institutions from January 2000 
to December 2007 using a registration/questionnaire sheet with more than 180 questions. 
Data regarding three tumor markers for HCC, specifically AFP, AFP-L3, and DCP, were 
beginning with the 16th survey. Therefore, the current study used the data from 2000 
(16th survey) to 2007 (18th survey, the latest). The data from 24029 patients contained 
all the laboratory variables necessary for calculating the BALAD and BALAD-2 scores, 
i.e., serum ALB, T-Bil, AFP, AFP-L3, and DCP at diagnosis of HCC, as well as the final 
prognosis (Figure 1). HCC was diagnosed on the basis of imaging studies, clinical data, 
or histopathologic studies at each institution. Treatment types were determined by the 
treatment algorithm for HCC proposed by Japanese guidelines (4). The patients were 
prospectively followed up at each institution. Most patients underwent ultrasonography 
and measurements of tumor markers every 3 or 4 months, and enhanced computed 
tomography (CT) or magnetic resonance imaging (MRI) every 6 or 12 months, 
according to the protocol of the Japanese guidelines (4). The prognosis of these 
registered patients was followed until confirmation of death in every survey. Although 
this study protocol was not submitted to the institutional review board of each 
institution that participated in the nationwide survey, the data collection and registration 
of patients with HCC were conducted with the approval of each institution. 
     BALAD and BALAD-2 scores were assessed in terms of their association with 
liver dysfunction, based on Child-Pugh class, and the progression of HCC on imaging 
examinations; progression was assessed based on tumor size, tumor multiplicity, portal 
vein invasion, and tumor stage. In addition, we used univariate and multivariate 
analyses to investigate whether BALAD and BALAD-2 scores discriminated the patient 
survival. Tumor staging was according to TNM criteria of LCSGJ (Supplementary 
table) (5). 
 
Calculating BALAD and BALAD-2 Scores 
     BALAD and BALAD-2 scores were calculated based on AFP, AFP-L3, DCP, 
ALB, and T-Bil levels measured in the serum sample obtained from each patient at the 
time of HCC diagnosis. The original BALAD score was calculated by simply summing 
the serum levels of factors indicating both tumor progression (AFP, AFP-L3, and DCP) 
and liver function (ALB and T-Bil) (1). The cut-offs for the elevations of AFP, AFP-L3, 
and DCP were 400 ng/dL, 15%, and 100 mAU/mL, respectively (1). Liver function was 
categorized based on serum ALB and T-Bil levels according to the method of Tateishi et 
al. (6). ALB level was categorized as above 3.5 g/dL, 2.8–3.5 g/dL, or below 2.8 g/dL, 
and scored as 0, 1, or 2, respectively. T-Bil level was categorized as below 1.0 mg/dL, 
1.0–2.0 mg/dL, or above 2.0 mg/dL, and scored as 0, 1, or 2, respectively. Liver 
function was then categorized based on the sum of these 2 scores as A (0 or 1), B (2 or 
3), or C (4). The BALAD score is based on the total number of elevated tumor markers 
and liver function scores. 
     The BALAD-2 score is calculated using the equation:  
Linear predictor (xb) = 0.02*(AFP – 2.57) + 0.012*(AFP-L3 – 14.19) + 0.19*(ln(DCP) 
– 1.93) + 0.17*((T-Bil [μmol/L]1/2) – 4.50) – 0.09*(ALB [g/L] – 35.11) , where T-Bil 1 
mg/dL = 17.1μmol/L, and AFP was capped at 50000 units. Both AFP and DCP are 
modeled as per 1000 units. Patients are stratified into four prognostic groups according 
to previously described cut-offs, resulting in four grades: score 1 (low risk, ≤ -1.74), 
score 2 (–0.91 to > –1.74), score 3 (0.24 to > –0.91), and score 4 (high risk, > 0.24) (2). 
     Because the actual values of AFP less than 15 ng/dL and DCP less than 40 
mAU/mL were not documented but described simple as “normal” in the data of 
nationwide follow-up surveys by LCSGJ, we randomly assigned the number 1 to 14 
ng/dL for AFP and 1 to 39 for DCP mAU/mL in cases with normal levels of these 
markers. We assigned 0% for AFP-L3 in cases with undetectable AFP-L3. 
 
Statistical Analyses 
     Differences in percentages between groups were analyzed using the chi-square 
test. Differences in means of quantitative values were analyzed using the 
Mann-Whitney U test. Changes in percentages and quantitative values of increases in 
BALAD and BALAD-2 scores were analyzed with the Cochran-Armitage test and 
Jonckheere-Terpstra test, respectively. The date of HCC diagnosis was defined as time 
zero for calculations of survival rates. Survival was defined as the time from diagnosis 
to death, or last follow-up if death had not occurred. Patients who died were not 
censored, while surviving patients were censored. The Kaplan-Meier method was used 
to calculate survival rates, and the log-rank test was used to analyze differences in 
survival. 
     The Cox proportional hazard regression model with backward elimination 
method was used for multivariate analysis. The factors analyzed were age, sex, 
Child-Pugh class, tumor size, tumor number, portal vein invasion, tumor stage, 
treatment, and BALAD and BALAD-2 scores. Statistical analysis was performed using 
JMP statistical software, version 11.0.0 (Macintosh version; SAS Institute, Cary, NC). 
All P values were derived from two-tailed tests, with P<0.05 accepted as statistically 
significant. 
 Results 
Baseline Patient Characteristics 
     The median follow-up period after diagnosis was 19.2 months, and the 25th and 
75th percentiles were 8.4 and 39.6 months, respectively. Table 1 shows the 
characteristics of study patients. Males comprised 70.1% of patients, and the mean age 
was 66.9 years. In the majority of patients, hepatitis C virus (HCV) antibody was 
positive and was as the cause of chronic liver disease. More than 70% of patients had 
Child-Pugh (7) class A liver function and HCC was stage I or II in more than 60% of the 
patients. Serum AFP and DCP levels were below the normal cut-offs (15 ng/mL and 40 
mAU/mL) in 33.7% and 42.9% of patients, respectively. Serum AFP-L3 was 
undetectable in 40.3% of patients. 
     On calculation of BALAD and BALAD-2 scores, patients were rated as having a 
BALAD score of 0, 1, 2, 3, 4, and 5 in 9658 (40.2%), 6756 (28.1%), 4135 (17.2%), 
2751 (11.4%), 499 (2.1%), and 230 (1.0%) of cases, respectively. BALAD-2 score was 
1, 2, 3, and 4 in 7827 (32.6%%), 6772 (28.2%%), 5510 (22.9%%), and 3920 (16.3%) of 
patients, respectively. 
 
Association of BALAD and BALAD-2 scores with Progression of HCC and Liver 
Function 
     Table 2 shows patient backgrounds as well as data on liver dysfunction and tumor 
progression based on BALAD and BALAD-2 scores. Increases in these scores were 
significantly associated with increased tumor size as well as higher percentages of 
patients with worse liver function (Child-Pugh A to C), multiple tumors, portal vein 
invasion, and increased TNM stage. The associations of BALAD-2 scores with liver 
dysfunction and tumor progression were more marked and consistent than those of 
BALAD scores. 
 
Prognostic Significance of BALAD and BALAD-2 scores 
     Patients’ median survival times and overall 3- and 5-year survival rates are shown 
in Table 3. Increases in both BALAD and BALAD-2 scores were associated with 
shortened median survival times and decreased 3- and 5-year survival rates. There were 
no overlaps in the 95% confidence intervals of median survival times between 
BALAD-2 scores, whereas there were some overlaps with BALAD. Multivariate 
analysis showed that BALAD and BALAD-2 scores were associated with patient 
survival independent of Child-Pugh class, tumor stage, and treatment (Table 4). 
 
Discrimination of Patient Survivals by BALAD and BALAD-2 scores 
     Figure 2 shows the post-diagnosis survival curves of patients based on BALAD 
and BALAD-2 scores. Both scores show good discriminatory ability for patient survival 
rates. In particular, there was no overlap in the 95% confidence intervals of survival 
curves when categorized by BALAD-2 scores. Figure 3 shows the post-diagnosis 
survival curves by BALAD-2 scores according to the etiology of background liver 
disease. BALAD-2 scores maintained a good discriminatory ability in all three patient 
subgroups without overlap of survival curves between scores. When patients were 
grouped based on the treatment of HCC (Figure 4), BALAD-2 scores proved equally 
discriminatory in all treatment classes without overlap of survival curves. In contrast, 
BALAD scores showed several overlaps between scores when patients were grouped by 
etiology or treatment (Supplementary figures 1 and 2). 
 
Discussion 
     The staging systems of HCC for assessment of patient outcomes are based on 
features that influence prognosis, which are broadly classified into two categories, 
namely, progression of tumors and severity of underlying liver dysfunction. Several 
staging systems / prognostic scores that combine these factors have been developed 
(8-13). In terms of staging, the progression of HCC is primarily evaluated by 
morphology, i.e., the size and number of tumors and the presence of portal vein invasion 
(5,14,15). Such evaluations are based mainly on imaging studies and postoperative 
pathologic examinations in patients who have undergone hepatic resection or 
transplantation. However, estimating tumor progression using imaging studies has 
several shortcomings. The detectability of liver tumors, which influences the 
determination of tumor multiplicity, depends on the resolution of the imaging modality 
(ultrasonography, CT, or MRI) and their quality, as well as the skill of the sonographer 
in case of ultrasonography. Recent advancements in imaging technology, such as 
multidetector-row CT (16,17), and MRI (18), have improved the detection of hepatic 
nodules, resulting in upstaging of HCC progression. In addition, discrepancies between 
imaging findings and pathologic results are often found in patients who undergo hepatic 
resection. With imaging studies, it is often difficult to detect microvascular invasion of 
HCC or minute satellite nodules, both of which are found in pathologic analysis after 
resection and result in upstaging of HCC progression. 
     Liver dysfunction in patients with HCC is usually estimated based on the 
Child-Pugh classification (7). This classification takes into account the presence and 
controllability of ascites and hepatic encephalopathy, in addition to prothrombin time 
and levels of serum ALB and T-Bil. However, the presence and controllability of ascites 
and hepatic encephalopathy are largely subjective. Therefore, HCC staging that is based 
on the morphological evaluation of tumor progression and on liver dysfunction as 
determined by Child-Pugh classification cannot be fully objective, and therefore cannot 
be standardized across regions. 
     The results of the present study, based on the data of a nationwide follow-up 
survey showed that staging systems based solely on serology were well associated with 
the progression of HCC and liver dysfunction, and had excellent discriminatory ability 
for survival in Japanese patients with HCC. The scores of the BALAD and BALAD-2 
models were associated with the survival of patients with HCC independent of 
Child-Pugh class and the morphological features of HCC (Table 4). Previous findings 
on the usefulness of the BALAD and BALAD-2 models for the prognostication of 
patients with HCC (1-3) were replicated in this large HCC cohort in Japan, where the 
survival of patients is long in comparison to Western and other Asian countries. 
Japanese patients are diagnosed at a much earlier stage, because individuals of the 
Japanese population who are at risk of HCC (those with chronic liver disease) are more 
rigorously screened than in Western and other Asian countries, and hence are much 
more likely to receive potentially curative therapy (19).  
     The three markers that are incorporated in the BALAD and BALAD-2 scores 
have the advantage of being commercially available, with regulatory approval in Japan, 
the United States, and Europe. All three markers are well documented to have 
prognostic significance when used individually (20-22) and in combination (23). In 
addition, previous studies revealed the prognostic significance of serum ALB and T-Bil 
levels as liver function measures in patients with HCC (6,24). The combination of these 
serological indicators of tumor progression and liver function accurately reflected the 
state of patients with HCC at diagnosis and categorized the risk of death thereafter, at 
least in Japan where the main etiology of HCC is HCV, many cases are diagnosed in the 
early stage, and the majority of patients have Child-Pugh class A liver function. In 
addition, these serological models, especially BALAD-2 model, maintained 
discriminatory ability in patient subgroups with hepatitis B virus (HBV) or 
non-HBV/HCV, or in those with intermediate or advanced stages, in addition to 
HCV-related HCC or early-stage HCC. 
     When comparing the original BALAD and BALAD-2 models, the latter had a 
marginally better discrimination. The overlap between risk groups was less evident for 
BALAD-2 (Table 4 and Figure 2). The superior discrimination of BALAD-2 model was 
enhanced when patients were grouped by disease stages. Also, regarding the association 
between BALAD and BALAD-2 scores and tumor progression and liver function, 
increases in BALAD-2 scores showed more consistent association with the progression 
of HCC and the deterioration of liver function (Table 3). 
     However, the serology-based staging models have several limitations. First, 
staging on the basis of serum markers is not applicable to diagnosis, although another 
serology-based model for the diagnosis of HCC has been reported (3,25). Although the 
selected treatments had close associations with the scores, especially of BALAD-2, 
these staging models cannot be used for treatment planning. In addition, these models 
are not applicable in patients who are taking drugs such as warfarin or vitamin K that 
can influence the levels of tumor markers, and it should be noted that the use of such 
drugs could not be verified in this study cohort. 
     There are several limitations of this study. The study patients were a part of all 
patients in nationwide survey (36.1%) in whom five laboratory variables necessary for 
calculating the BALAD and BALAD-2 scores were available, although the distributions 
of HCC stage and Child-Pugh class, as well as tumor size, number, and portal vein 
invasion, were same between 24029 study patients and 42525 patients excluded from 
the study due to the lack of laboratory variables (data not sown). In addition, actual 
levels of AFP and DCP were not available in patients with AFP below 15 ng/dL and 
patients with DCP below 40 mAU/mL and values within these reference ranges were 
randomly assigned for the calculation of BALAD-2 scores in these cases. Finally, the 
prognoses of patients who underwent transplantation based on these scores are not 
known, because few patients with HCC are treated with transplantation in Japan. 
     In conclusion, we evaluated the prognostic significance of the serology-based 
BALAD and BALAD-2 scoring models in Japanese patients with HCC in a cohort of a 
nationwide follow-up survey, and confirmed that these models are applicable for these 
patients. 
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Figure Legends 
Figure 1. Scelection flowchart of the study patients in a cohort of a Japanese nationwide 
survey of patients with HCC. 
 
Figure 2. Survival rates of patients with hepatocellular carcinoma (HCC) after diagnosis 
based on (A) BALAD and (B) BALAD-2 scores evaluated by serum levels of the 
following measured at the diagnosis of HCC: ALB, T-Bil, AFP, AFP-L3, and DCP. 
Dotted lines, 95% confidence intervals (CIs). BALAD-2 had an excellent 
discriminatory ability for patient survival with little overlap of 95% CIs between 
groups. 
 
Figure 3. Survival rates of patients with hepatocellular carcinoma (HCC) after diagnosis 
by BALAD-2 scores evaluated by serum levels of the following measured at the 
diagnosis of HCC: ALB, T-Bil, AFP, AFP-L3, and DCP. A) Patients with hepatitis B 
virus (HBV) infection; B) Patients with hepatitis C virus (HCV) infection; C) Patients 
without hepatitis virus infection (non-HBV/HCV). 
 Figure 4. Survival rates of patients with hepatocellular carcinoma (HCC) who 
undergone A) curative, B) intermediate, and C) palliative or no treatment after diagnosis 
by BALAD-2 scores evaluated by serum levels of the following measured at the 
diagnosis of HCC: ALB, T-Bil, AFP, AFP-L3, and DCP. 
 
Supplementary figure 1. Survival rates of patients with hepatocellular carcinoma (HCC) 
after diagnosis by original BALAD scores evaluated by serum levels of the following 
measured at the diagnosis of HCC: ALB, T-Bil, AFP, AFP-L3, and DCP. A) Patients 
with hepatitis B virus (HBV) infection; B) Patients with hepatitis C virus (HCV) 
infection; C) Patients without hepatitis virus infection (non-HBV/HCV). 
 
Supplementary figure 2. Survival rates of patients with hepatocellular carcinoma (HCC) 
who undergone A) curative, B) intermediate, and C) palliative or no treatment after 
diagnosis by original BALAD scores evaluated by serum levels of the following 
measured at the diagnosis of HCC: ALB, T-Bil, AFP, AFP-L3, and DCP. 
Table 1. Patient characteristics (n = 24029) 
Age (mean ± SD, years) (median, IQR) 66.9 ± 9.6 (68, 61-74) 
Sex ratio (male / female) 16850 (70.1) / 7179 (29.9) 
HBsAg (positive / negative) 3724 (16.0) / 19618 (84.0) 
HCV-Ab (positive / negative) 16352 (69.5) / 7186 (30.5) 
Child-Pugh class (A / B / C)** 17533 (74.3) / 5230 (22.1) / 846 (3.6) 
Albumin (mean ± SD, g/dL) 3.63 ± 0.56 
Total bilirubin (mean ± SD, mg/dL) 1.13 ± 1.44 
Prothrombin (mean ± SD, %) 81.2 ± 16.6 
Platelet count (mean ± SD, x1000/mL) 127 ± 71 
Tumor size (mean ± SD, cm) (median, 
IQR) 
3.92 ± 3.70 (2.8, 2.0–4.5) 
          ≤2 cm / >2 cm 7966 (34.2) / 15318(65.8) 
Number of tumors (single/multiple) 13381 (57.0) / 10107 (43.0) 
Portal vein invasion (absent/present)* 19876 (88.1) / 2680 (11.9) 
AFP (median, IQR)*, <15 ng/mL (%) 175.0 (46.0–974.5), 8086 (33.7) 
          <400 ng/mL / ≥ 400 ng/mL 21560 (89.7) / 2469 (10.3) 
AFP-L3 (median, IQR)*, undetected (%) 21.0 (5.6–49.7), 9682 (40.3) 
          <15% / ≥ 15% 20152 (83.7) / 3877 (16.3) 
DCP (median, IQR)*, <40 mAU/mL 283.0 (92.0–1240.0), 10297 (42.9) 
          <100 mAU/mL / ≥ 100 
mAU/mL 
19037 (79.2) / 4992 (20.8) 
TNM stage (I / II / III / IV) 4791 (22.3) / 8943 (41.6) / 5684 (26.4) / 
2081 (9.7) 
Treatment (resection / LAT / TACE / 
others / none) 
6859 (28.6) / 8600 (35.8) / 6221 (25.9) / 
1378 (5.8) / 934 (3.9) 
Percentages are given in parentheses. 
HBsAg, hepatitis B virus surface antigen; HCV-Ab, hepatitis C virus antibody; AFP, 
alpha-fetoprotein; AFP-L3, lens culinaris agglutinin-reactive AFP; DCP, 
des-gamma-carboxy prothrombin; LAT, locoregional ablative therapies; TACE, 
transarterial chemoembolization. 
Data were missing in 687 cases for HBsAg, 491 for HCV-Ab, 420 for Child-Pugh class, 
706 for prothrombin time, 256 for platelet counts, 745 for tumor size, 541 for tumor 
number, 1473 for portal vein invasion, 2530 for TNM stage, and 37 for treatment. 
*Based on imaging studies. 
 
Table 2. Association of BALAD and BALAD-2 scores with hepatitis viral 
infection, liver function, tumor progression, and treatment in patients with 
hepatocellular carcinoma (n = 24029) 
BALAD score 0 
(n = 9568) 
1 
(n = 6756) 
2 
(n = 4135) 
3 
(n = 2751) 
4 
(n = 499) 
5 
(n = 230) 
P value 
Age 67.4 ± 8.8 67.5 ± 9.6 66.3 ± 10.2 65.4 ± 10.6 63.9 ± 9.6 62.7 ± 10.2 <0.0001 
Sex-male 6561 (67.9) 4879 (72.2) 2875 (69.5) 1995 (72.5) 363 (72.8) 177 (77.0) <0.0001 
HBsAg positive 1169 (12.5) 1002 (15.2) 781 (19.5) 605 (22.6) 106 (22.0) 61 (27.9) <0.0001 
HCV-Ab positive 7283 (76.9) 4540 (68.6) 2594 (64.2) 1544 (57.2) 278 (57.1) 113 (52.8) <0.0001 
Child-Pugh class-A 7992 (84.3) 5195 (78.4) 2665 (65.6) 1659 (61.2) 22 (4.5) 0 <0.0001 
Child-Pugh class-B 1480 (15.6) 1377 (20.8) 1170 (28.8) 818 (30.2) 300 (60.7) 85 (37.6) <0.0001 
Child-Pugh class-C 214 (0.1) 57 (0.8) 229 (5.6) 233 (8.6) 172 (34.8) 141 (62.4) <0.0001 
Platelet count 117 ± 61 131 ± 69 132 ± 78 147 ± 89 125 ± 86 142 ± 94 <0.0001 
Tumor size 2.65 ± 2.62 4.05 ± 3.04 4.81 ± 4.31 6.42 ± 5.02 6.13 ± 5.05 8.34 ± 7.08 <0.0001 
Tumor number-solitary 6217 (65.1) 3813 (57.5) 2038 (50.7) 1130 (43.1) 128 (27.7) 55 (26.6) <0.0001 
Tumor number-multiple 3328 (34.9) 2822 (42.5) 1979 (49.3) 1492 (56.9) 334 (72.3) 152 (73.4) <0.0001 
Portal vein invasion –* 8957 (98.1) 5795 (91.3) 3143 (81.1) 1649 (64.8) 254 (56.0) 78 (37.9) <0.0001 
Portal vein invasion +* 171 (1.9) 552 (8.7) 732 (18.9) 897 (35.2) 200 (44.0) 128 (62.1) <0.0001 
TNM stage-1 3120 (35.5) 1048 (17.3) 459 (12.5) 135 (5.6) 23 (5.8) 6 (3.4) <0.0001 
TNM stage-2 3935 (44.8) 2765 (45.6) 1429 (38.9) 714 (29.7) 76 (19.0) 24 (13.5) <0.0001 
TNM stage-3 1603 (18.3) 1838 (30.3) 1223 (33.2) 841 (35.0) 137 (34.3) 42 (23.6) <0.0001 
TNM stage-4 119 (1.4) 413 (6.8) 567 (15.4) 713 (29.7) 163 (40.9) 106 (59.5) <0.0001 
Treatment-resection 2422 (25.1) 2273 (33.7) 1283 (31.1) 826 (30.1) 45 (9.0) 10 (4.3) 0.9873 
Treatment-LAT 5190 (53.9) 2054 (30.4) 923 (22.4) 356 (12.9) 63 (12.6) 14 (6.1) <0.0001 
Treatment-TACE 1792 (18.6) 1974 (29.3) 1342 (32.5) 901 (32.8) 167 (33.5) 45 (19.6) <0.0001 
Treatment-others 118 (1.2) 285 (4.2) 377 (9.1) 424 (15.4) 109 (21.8) 65 (28.3) <0.0001 
Treatment-none 117 (1.2) 162 (2.4) 203 (4.9) 241 (8.8) 115 (23.1) 96 (41.7) <0.0001 
 
BALAD-2 score 1 
(n=7827) 
2 
(n=6772) 
3 
(n=5510) 
4 
(n=3920) 
P value 
Age 67.5 ± 9.3 67.6 ± 9.4 66.8 ± 9.7 64.6 ± 9.9 <0.0001 
Sex-male 5560 (71.0) 4699 (69.4) 3828 (69.5) 2763 (70.5) 0.3006 
HBsAg positive 1170 (15.4) 983 (14.9) 842 (15.7) 729 (19.2) <0.0001 
HCV-Ab positive 5453 (71.2) 4744 (71.2) 3749 (69.4) 2406 (62.9) <0.0001 
Child-Pugh class-A 7542 (96.7) 5691 (85.7) 3491 (64.6) 899 (23.3) <0.0001 
Child-Pugh class-B 257 (3.3) 943 (14.2) 1863 (34.5) 2167 (56.2) <0.0001 
Child-Pugh class-C 2 (0.0) 5 (0.1) 48 (0.9) 791 (20.5) <0.0001 
Platelet count 139 ± 63 126 ± 66 120 ± 76 117 ± 86 <0.0001 
Tumor size 3.00 ± 2.88 3.70 ± 3.48 4.54 ± 4.13 5.53 ± 5.10 <0.0001 
Tumor number-solitary 5232 (67.7) 3909 (58.7) 2737 (51.0) 1503 (40.3) <0.0001 
Tumor number-multiple 2499 (32.3) 2747 (41.3) 2632 (49.0) 2229 (59.7) <0.0001 
Portal vein invasion – 7209 (97.1) 5843 (92.0) 4357 (84.5) 2467 (68.0) <0.0001 
Portal vein invasion + 217 (2.9) 505 (8.0) 797 (15.5) 1161 (32.0) <0.0001 
TNM stage-1 2209 (30.9) 1324 (21.6) 817 (16.7) 441 (13.2) <0.0001 
TNM stage-2 3403 (47.6) 2727 (44.6) 1861 (38.0) 952 (28.5) <0.0001 
TNM stage-3 1383 (19.4) 1704 (27.9) 1559 (31.9) 1038 (31.1) <0.0001 
TNM stage-4 153 (2.1) 360 (5.9) 657 (13.4) 911 (27.2) <0.0001 
Treatment-resection 2776 (35.5) 2217 (32.8) 1348 (24.5) 518 (13.2) <0.0001 
Treatment-LAT 3530 (45.2) 2509 (37.1) 1701 (30.9) 860 (22.0) <0.0001 
Treatment-TACE 1302 (16.7) 1716 (25.4) 1831 (33.3) 1372 (35.0) <0.0001 
Treatment-others 117 (1.5) 211 (3.1) 428 (7.8) 622 (15.9) <0.0001 
Treatment-none 88 (1.1) 107 (1.6) 194 (3.5) 934 (13.9) <0.0001 
Percentages are given in parentheses. 
HBsAg, hepatitis B virus surface antigen; HCV-Ab, hepatitis C virus antibody; LAT, 
locoregional ablative therapies including radiofrequency ablation and percutaneous 
ethanol injection; TACE, transarterial chemoembolization. 
Data were missing in 687 cases for HBsAg, 491 for HCV-Ab, 420 for Child-Pugh class, 
706 for prothrombin time, 256 for platelet counts, 745 for tumor size, 541 for tumor 
number, 1473 for portal vein invasion, 2530 for TNM stage, and 37 for treatment. 
*Based on imaging studies. 
 
Table 3. Median survival times and 3- and 5-years survival rates for 
BALAD and BALAD-2 scores in patients with hepatocellular carcinoma (n 
= 24029) 
  N Median 
survival 
(years) 
95% 
CI 
3-year 
survival 
(%) 
95% CI 5-year 
survival 
(%) 
95% CI 
BALAD 
score 
0 9658 7.7 7.3–
9.4 
85.2 84.3–
86.1 
68.0 66.3–
69.5 
1 6576 5.4 5.1–
5.8 
70.0 68.5–
71.4 
52.4 50.4–
54.4 
2 4135 3.7 3.3–
4.0 
55.2 53.1–
57.1 
41.7 39.3–
44.1 
3 2751 2.0 1.8–
2.2 
41.0 38.6–
43.4 
29.4 26.6–
32.1 
4 499 0.8 0.8–
0.9 
24.4 19.4–
29.7 
15.9 11.0–
21.5 
5 230 0.3 0.2–
0.4 
10.8 6.2–
16.9 
7.0 3.1–
13.0 
BALAD-2 
score 
1 7827 9.7 8.3– 86.9 85.9–
87.8 
72.5 70.8–
74.1 
2 6772 5.8 5.5–
6.2 
74.8 73.4–
76.2 
55.8 53.8–
57.8 
3 5510 3.8 3.6–
4.0 
57.1 55.4–
58.9 
40.4 38.2–
42.6 
4 3920 1.8 1.7–
1.9 
37.7 35.7–
39.5 
25.4 23.2–
27.7 
CI, confidence interval. 
 
 
 
Table 4. Multivariate analysis with backward elimination method for 
factors associated with survival after diagnosis in patients with 
hepatocellular carcinoma (n = 24029) 
Factor  Multivariate analysis 
  P value Relative risk (95% CI) 
Age per 1.0 <0.0001 1.011 (1.008–1.014) 
Sex female   
 male <0.0001 1.128 (1.062–1.198) 
Child-Pugh class A  1 
 B <0.0001 1.631 (1.534–1.736) 
 C <0.0001 1.779 (1.565–2.022) 
Tumor size per 1.0 <0.0001 1.019 (1.014–1.024) 
Portal vein invasion* Absent  1 
 Present <0.0001 1.320 (1.193–1.460) 
TNM stage 1  1 
 2 <0.0001 1.279 (1.172–1.397) 
 3 <0.0001 1.757 (1.601–1.929) 
 4 <0.0001 2.890 (2.528–3.304) 
Treatment None  1 
 Resection <0.0001 0.278 (0.245–0.315) 
 LAT <0.0001 0.362 (0.319–0.410) 
 TACE <0.0001 0.520 (0.462–0.585) 
 Others <0.0001 0.730 (0.641–0.832) 
BALAD score 0  1 
 1 <0.0001 1.443 (1.339–1.556) 
 2 <0.0001 1.892 (1.743–2.053) 
 3 <0.0001 2.579 (2.358–2.821) 
 4 0.0005 2.634 (2.247–3.087) 
 5 0.0005 3.846 (3.104–4.766) 
 
Factor  Multivariate analysis 
  P value Relative risk (95% CI) 
Age per 1.0 <0.0001 1.011 (1.008–1.014) 
Sex female   
 male <0.0001 1.129 (1.063–1.199) 
Child-Pugh class A  1 
 B <0.0001 1.293 (1.207–1.386) 
 C <0.0001 1.598 (1.406–1.816) 
Tumor size per 1.0 <0.0001 1.021 (1.016–1.026) 
Number of tumors single   
 multiple 0.0065 1.117 (1.032–1.211) 
Portal vein invasion* Absent  1 
 Present <0.0001 1.263 (1.137–1.404) 
TNM stage 1  1 
 2 <0.0001 1.384 (1.263–1.516) 
 3 <0.0001 2.073 (1.839–2.336) 
 4 <0.0001 3.607 (3.044–4.274) 
Treatment None  1 
 Resection <0.0001 0.301 (0.265–0.342) 
 LAT <0.0001 0.356 (0.314–0.404) 
 TACE <0.0001 0.525 (0.467–0.591) 
 Others <0.0001 0.770 (0.676–0.878) 
BALAD-2 score 1  1 
 2 <0.0001 1.505 (1.387–1.632) 
 3 <0.0001 2.128 (1.957–2.314) 
 4 <0.0001 2.816 (2.545–3.116) 
CI, confidence interval; LAT, locoregional ablative therapies; TACE, transarterial 
chemoembolization. 
*Based on imaging studies. 
 
 
 
  
 
